Charles Brenner, a metabolic regulation researcher who left City of Hope for the University of Helsinki, Finland.

Charles Brenner

NAD Metabolism

RESEARCH FIELD

NAD Metabolism

Mitochondrial Bioenergetics

Education

Wesleyan University

B.S.

Molecular Biology

,

1983

Stanford University

Ph.D

Oncology and Cancer Biology

,

1993

Brandeis University

Postdoc

X-ray crystallography

,

1993

-

1996

Summary

Charles Brenner is a metabolic regulation researcher who left the City of Hope research institute in the United States to become Professor of Metabolic Regulation at the University of Helsinki, in its joint Faculties of Medicine and Pharmacy and its HiLIFE institute. He was recruited with support of the Research Council of Finland, in the same initiative that brought Halley Froehlich, according to the University of Helsinki's announcement of June 2, 2026.

At City of Hope's Beckman Research Institute, Brenner held the inaugural Alfred E. Mann Family Foundation Chair of the Department of Diabetes & Cancer Metabolism. Before that, he was the Roy J. Carver Chair and head of biochemistry at the University of Iowa.

Brenner is a leading figure in nicotinamide adenine dinucleotide (NAD) metabolism. His laboratory, established in 1996, developed targeted quantitative methods for NAD metabolomics, discovered the nicotinamide riboside (NR) kinase and nucleosidase pathways to NAD, and ran the first human trial of NR as an NAD+ precursor. His work has shown how the NAD system is disrupted in conditions of metabolic stress. More recently he has studied citrin deficiency, a rare disease involving loss of SLC25A13, identifying glycerol-3-phosphate as the activator of ChREBP and a mechanism linking the disease to sweet aversion and metabolic dysfunction-associated steatotic liver disease (MASLD).

CURRENT AFFILIATION

University of Helsinki — joint Faculties of Medicine and Pharmacy, HiLIFE, Finland

Recruitment Program

Research Council of Finland